Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
批准号:
10603636
负责人:
Rajesh Krishnan
金额:
$75.37万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-03-15 至 2025-02-28
关键词:
Androgen ReceptorAnimal ModelApplications GrantsAreaAwardBindingBinding ProteinsBiological AssayBiological AvailabilityCaco-2 CellsCastrationChemistryClinicalDataDevelopmentDevelopment PlansDiseaseDoseDrug KineticsEngineeringEvaluationFollow-Up StudiesFormulationFundingGeneticGrantHormone ReceptorIn VitroIndustryInvestigational New Drug ApplicationKennedy SyndromeKnock-outManualsMedicalMetabolicMitochondriaMusculoskeletalMutagenicity TestsN-terminalNeurodegenerative DisordersNeuronsOralPathologicPathway interactionsPatientsPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsPhasePhenotypePlasma ProteinsPre-Clinical ModelProcessProductivityPropertyProteinsReceptor ActivationReceptor AggregationRecordsRegulatory AffairsResearchRodentSafetySeriesSignal TransductionSmall Business Innovation Research GrantSmall Business Technology Transfer ResearchSpinobulbar Muscular AtrophyTestosteroneTherapeuticTherapeutic AgentsToxic effectToxicokineticsToxicologyTransgenic MiceTransgenic ModelUbiquitinUnited States Food and Drug Administrationadvanced prostate cancerandrogen sensitiveandrogenicantagonistcross reactivitydrug candidatedrug developmenteffective therapyefficacy evaluationefficacy studyexperienceexperimental studyin vivomanufacturemanufacturing processmedication safetymotor neuron degenerationmulticatalytic endopeptidase complexmutantneurotoxicnovel therapeuticspharmacologicphase I trialpolyglutaminepre-Investigational New Drug meetingpre-clinicalpreclinical developmentpreclinical efficacyprocess optimizationprotein degradationreceptorsafety studyscale upskeletal muscle wastingsmall molecule therapeuticsstem cell differentiation
中文摘要
项目总结
肯尼迪病,也被称为脊髓延髓肌萎缩症(SBMA),是一种进行性的
遗传性聚谷氨酰胺N-末端结构域扩张引起的神经退行性疾病
雄激素受体(AR)的NTD。最近的研究表明,突变的AR蛋白
错误折叠,聚集,并异常地与其他蛋白质相互作用,导致雄激素-
依赖性下运动神经元变性和骨骼肌萎缩。目前,有以下几种
没有可用的治疗方法来减缓、阻止甚至逆转SBMA的进展,因此,
未得到满足的医疗需求很高,需要发现新的治疗剂。AR途径是一个非常重要的途径
SBMA正在研究的重要领域。SBMA-HAD治疗的实验研究
重点研究AR与睾丸素的相互作用。动物去势去除睾酮的实验研究
机型似乎具有保护性,并恢复了一些失去的功能。SBMA患者的AR基因敲除-
分化为神经元的干细胞逆转了突变AR的神经毒性效应。
这导致了SBMA治疗中使用抗雄激素疗法。我们获奖的第一阶段SBIR
GRANT在临床前评估我们的NTD结合的选择性AR拮抗剂和降解剂(DAARI)
SBMA的模型提供了强有力的活体数据,支持本阶段2的提交
应用来继续ONCT-505的临床前开发,这是一种潜在的SBMA疗法。
我们的目标是为ONCT-505生成最终支持提交的某些数据
研究中的新药(IND)申请。ONCT-505已经在不同的领域进行了研究
AR依赖疾病的临床前模型,包括SBMA和晚期前列腺癌。
重要的是,ONCT-505与任何其他靶向AR的分子不同,它与AR激活相结合
NTD中的功能-1(AF-1)结构域,导致信号拮抗,最终导致AR蛋白
通过泛素/蛋白酶体途径降解。ONCT-505口服生物利用度为
适合于药物开发的药代动力学(PK)和类药物性质
在SBMA临床前模型中的疗效优于手术去势。分子没有显示出
在试点毒理学中,显性毒性高达ED50(有效剂量为50%观察到的疗效)的200倍
研究也缺乏与其他蛋白质的交叉反应。这些特性使ONCT-505成为
作为治疗患者的潜在小分子药物的理想候选者
来自SBMA。
成功完成概述的研究将产生一种临床候选药物
已证明的临床前疗效、良好记录的安全性和可扩展的GMP兼容性
制造过程。
英文摘要
PROJECT SUMMARY
Kennedy’s disease, also known as spinobulbar muscular atrophy (SBMA), is a progressive
neurodegenerative disease caused by genetic polyglutamine expansion in the N-terminal domain
(NTD) of the androgen receptor (AR). Recent research has shown that the mutant AR protein
misfolds, aggregates, and abnormally interacts with other proteins, leading to androgen-
dependent lower motor neuron degeneration and skeletal muscle atrophy. Currently, there are
no treatments available to slow, stop or even reverse the progression of SBMA, therefore, the
unmet medical need is high to discover novel therapeutic agents. The AR pathway is a very
important area being studied in SBMA. Experimental studies for the treatment of SBMA have
focused on interaction of the AR with testosterone. Removing testosterone via castration in animal
models appears to be protective and restores some lost function. AR knockout in SBMA patient-
derived stem cells differentiated into neurons reverses the neurotoxic effects of the mutant AR.
This led to the use of anti-androgenic therapies for SBMA treatment. Our awarded Phase 1 SBIR
grant to evaluate our NTD-binding selective AR antagonists and degraders (DAARIs) in preclinical
models of SBMA has provided strong in vivo data that support the submission of this Phase 2
application to continue the preclinical development of ONCT-505 a potential SBMA therapy.
Our objective is to generate certain data for ONCT-505 that will ultimately support the submission
of an investigational new drug (IND)-application. ONCT-505 has been studied in various
preclinical models of AR-dependent diseases, including SBMA and advanced prostate cancer.
Importantly, ONCT-505, unlike any other molecule targeting the AR, binds to the AR activation
function-1 (AF-1) domain in the NTD and leads to signaling antagonism and ultimately AR protein
degradation via ubiquitin/proteasome pathway. ONCT-505 is orally bioavailable with
pharmacokinetic (PK) and drug-like properties suitable for drug development and demonstrated
efficacy in SBMA preclinical models better than surgical castration. The molecule did not show
overt toxicity up to 200 times the ED50 (effective dose of 50% observed efficacy) in pilot toxicology
studies and also lacks cross-reactivity with other proteins. These properties make ONCT-505 an
ideal candidate for further evaluation as potential small molecule therapeutic for patients suffering
from SBMA.
Successful completion of the outlined studies will result in a clinical drug candidate with
demonstrated preclinical efficacy, well-documented safety profile, and scalable GMP-compatible
manufacturing process.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development
-
批准号:10473797
-
项目类别:
-
资助金额:$102.32万
-
财政年份:2021
-
负责人:Rajesh Krishnan
-
依托单位:
海外基金